



AU9463802

(12) PATENT ABRIDGMENT (11) Document No. AU-B-63802/94
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 682348

- (54) Title
(S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE (S)-MALATE AND ITS USE AS A MEDICAMENT
- International Patent Classification(s)
(51)⁵ **C07D 213/38 A61K 031/44**
- (21) Application No. : **63802/94** (22) Application Date : **29.03.94**
- (87) PCT Publication Number : **WO94/22831**
- (30) Priority Data
- | (31) Number | (32) Date | (33) Country |
|-------------------|-----------------|---|
| GB 9300689 | 01.04.93 | WO WORLD INTELLECTUAL PROPERTY ORGANIZATION (WIPO) |
| 9320273 | 01.10.93 | GB UNITED KINGDOM |
- (43) Publication Date : **24.10.94**
- (44) Publication Date of Accepted Application : **02.10.97**
- (71) Applicant(s)
ASTRA AKTIEBOLAG
- (72) Inventor(s)
ROBERT JOHN MURRAY; DONALD MATHISEN; MICHEL BALESTRA
- (74) Attorney or Agent
E F WELLINGTON & CO , 312 St Kilda Road, MELBOURNE VIC 3004
- (56) Prior Art Documents
WO 93/20052
- (57) Claim

1. A selected (S)- α -phenyl-2-pyridineethanamine salt having useful pharmacokinetic properties such that when used in the treatment of neurodegenerative disorders in a patient, the blood plasma concentration obtained is linearly proportional to the dose administered, said selected salt being the (S)- α -phenyl-2-pyridineethanamine (S)-malate, in having non-hygroscopic property effective to provide such stability as to be ideally suitable for pharmaceutical formulation.



INTE

(51) International Patent Classification ^S : C07D 213/38, A61K 31/44		A1	(11) International Publication Number: WO 94/22831 (43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/GB94/00651 (22) International Filing Date: 29 March 1994 (29.03.94) (30) Priority Data: PCT/GB93/00689 1 April 1993 (01.04.93) WO <i>(34) Countries for which the regional or international application was filed:</i> GB et al. 9329273.7 1 October 1993 (01.10.93) GB		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	
(71) Applicant (for all designated States except MN): FISONS CORPORATION (US/US); Jefferson Road, P.O. Box 1710, Rochester, NY 14603 (US). (71) Applicant (for MN only): FISONS PLC (GB/GB); Fison House, Princes Street, Ipswich, Suffolk IP1 1QH (GB). (72) Inventors: MURRAY, Robert, John; 172 Lac Kine Drive, Brighton, NY 14618 (US). MATHISEN, Donald; 25 Southcross Trail, Fairport, NY 14450 (US). BALESTRA, Michel; 8 Sungrove Lane, Rochester, NY 14624 (US). (74) Agent: HAYLES, James, Richard; Fisons plc, 12 Derby Road, Loughborough, Leicestershire LE11 0BB (GB).		(71) ASTRA AKTIEBOLAG S-151 85 Soderfalje Sweden 682348	
(54) Title: (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE (S)-MALATE AND ITS USE AS A MEDICAMENT			
(57) Abstract (S)- α -phenyl-2-pyridineethanamine (S)-malate is useful in the treatment of neurodegenerative disorders. It is an anticonvulsant and a neuroprotective agent.			



(S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE (S)-MALATE AND ITS USE AS A MEDICAMENT

This invention relates to (S)- α -phenyl-2-pyridineethanamine (S)-malate, its use as a pharmaceutical, in particular in the treatment of neurodegenerative disorders, a process for its production, and pharmaceutical formulations including it.


5 A major problem with existing drugs used to treat neurodegenerative disorders is a lack of predictability in the concentration of a drug in a patient's blood plasma resulting from administration of a given quantity of that drug, *i.e.* existing drugs do not exhibit linear pharmacokinetics. It has been stated that an ideal drug in this field would show a linear relationship between blood plasma concentration and dose size so that a given change
10 in dose would yield a predictable change in blood plasma concentration of the drug ['Pharmacokinetics of old, new and yet-to-be discovered antiepileptic drugs', R H Levy and B M Kerr, *Epilepsia*, vol 30, Supp 1, S35-S41, 1989].

Europe Patent Application 356035 discloses a large number of compounds for use in the treatment of neurodegenerative disorders, including α -phenyl-2-pyridineethanamine
15 [referred to therein as 1-phenyl-2-(2-pyridinyl)ethylamine]. The (S)-enantiomer of this compound, and its pharmaceutically acceptable acid addition salts, have been found to exhibit linear pharmacokinetics, and are disclosed in WO 93/20052 (International Patent Application N° PCT/GB93/00689).

Surprisingly, it has now been found that the (S)-malate salt of
20 (S)- α -phenyl-2-pyridineethanamine has an exceptional advantage in use, by being effectively non-hygroscopic and providing outstanding stability to moisture, such as to be ideally suitable for pharmaceutical formulation, besides having improved pharmacokinetic properties such that when used in the
25 treatment of neurodegenerative disorders in a patient, the blood plasma concentration obtained is linearly proportional to the dose administered.



In an embodiment of the invention, there is provided (S)- α -phenyl-2-pyridineethanamine (S)-malate:



(referred to herein as "the compound of the invention") which is greater than 90%
5 enantiopure.

By "greater than 90% enantiopure" we mean that each enantiomeric component of the salt is greater than 90% enantiopure, *i.e.* each enantiomeric component contains less than 10% by weight of the corresponding (*R*)-enantiomer.

10 Preferably, the compound of the invention is more than 99% enantiopure, most preferably as close to 100% enantiopure as known methods of optical purification (*e.g.* fractional crystallization, chiral chromatography), chiral starting materials and/or chiral synthesis will allow.

15 The invention also provides a method of preparation of (S)- α -phenyl-2-pyridineethanamine (S)-malate which comprises: (a) precipitation from a solution of a mixture of (S)- α -phenyl-2-pyridineethanamine, or a salt thereof, and (S)-malic acid which is greater than 90% enantiopure; or (b) precipitation from a solution of a mixture of (S)- α -phenyl-2-pyridineethanamine or a salt thereof, which is greater than 90%
20 enantiopure, and (S)-malic acid which is greater than 90% enantiopure. α -Phenyl-2-pyridineethanamine and (S)- α -phenyl-2-pyridineethanamine may be prepared by the method of Example 1 below.



Thus the present invention provides a selected (S)- α -phenyl-2-pyridineethanamine salt having useful pharmacokinetic properties such that when used in the treatment of neurodegenerative disorders in a patient, the blood plasma concentration obtained is linearly proportional to the dose administered, said selected salt being the (S)- α -phenyl-2-pyridineethanamine (S)-malate, in having non-hygroscopic property effective to provide such stability as to be ideally suitable for pharmaceutical formulation.

In summary, we have found that the (S)-malate salt of (S)- α -phenyl-2-pyridineethanamine (as well as the benzoate salt of (S)- α -phenyl-2-pyridineethanamine, which is the subject of our copending Application No. 64337/94) is relatively unique in being respectively the only salt of the pharmaceutically acceptable salts of (S)- α -phenyl-2-pyridineethanamine, having non-hygroscopic property effective to provide such stability as to be ideally suitable for pharmaceutical formulation, besides having improved pharmacokinetic properties such that when used in the treatment of neurodegenerative disorders in a patient, the blood plasma concentration obtained is linearly proportional to the dose administered. As a result of this finding: (a) a substantial advantage as indicated is gained; (b) the advantage is possessed by the selected salt; and (c) the advantage can be said to be peculiar to the selected salt, with the single exception specified above.

The compound of the invention is indicated as a pharmaceutical, in particular as an anticonvulsant and a neuroprotective agent in the treatment of neurodegenerative disorders. Specific neurodegenerative disorders that may be mentioned include stroke, cerebral ischaemia, cerebral palsy, the effects of hypoglycaemia, epilepsy, AIDS-related dementia, Alzheimer's disease, Huntington's chorea, Olivo-ponto-cerebellar atrophy, perinatal asphyxia, Parkinson's disease, anoxia, neuronal damage associated with substance abuse (for example, narcotics or cocaine), retinopathies, schizophrenia, ischaemic states after cardiac arrest or surgical operations, intoxication or injuries of the spinal



cord and amyotrophic lateral sclerosis. Anticonvulsant therapy in epilepsy, and neuro-protective therapy in stroke, cerebral ischaemia and anoxia are of particular interest.

While not being limited by theory, neurodegeneration is thought to be caused or accelerated by certain excitatory amino acids found naturally in the central nervous system (CNS). Glutamate is an endogenous amino acid which has been characterized as a fast excitatory transmitter in the mammalian brain. Glutamate is also known as a powerful neurotoxin capable of killing CNS neurons under certain pathologic conditions which accompany stroke and cardiac arrest. It has been shown that the sensitivity of central neurons to hypoxia and ischaemia can be reduced by the specific antagonism of post synaptic glutamate receptors. Glutamate is characterized as a broad spectrum agonist having activity at four neuronal excitatory amino acid receptor sites. These receptor sites are named after the amino acids which selectively excite them: kainate (KA), N-methyl-D-aspartate (NMDA), quisqualate (QUIS) and 2-amino-4-phosphonobutyrate (APB). Glutamate is believed to be a mixed agonist capable of binding to and exciting all four receptor types. Thus, agents which selectively block or antagonise the action of glutamate at these receptors can prevent neurotoxic injury associated with anoxia, hypoxia or ischemia. In particular, compounds which bind to the NMDA receptor site and selectively block the action of glutamate are useful in the prevention and treatment of neurodegenerative diseases.

The pharmacological activity of the compound of the invention may be measured in the tests set out below.

- a) **NMDA blocking activity** is measured by assessing a compound's ability to protect mice from convulsions induced by intravenous administration of 150mg/kg of NMDA according to the procedures of Czuczwar *et al*, (Neurotransmitters, Seizures and Epilepsy III, edited by G Nistico *et al*, Raven Press, New York 1986, pages 235-246). Groups of mice are pretreated by 30 minutes with the test compound by the intraperitoneal route and then given NMDA. Animals are observed for convulsions as defined by loss of righting reflex and appearance of tonic/clonic seizures. Animals are kept for 60 minutes after NMDA dosing and mortality is recorded.

- b) **NMDA receptor antagonist activity** may be measured *in vitro* by assaying a compound's ability to inhibit binding of the receptor antagonist 10,11-dihydro-5-methyl-5H-dibenzo[a,d]-cyclohepten-5,10-imine (MK 801) to the receptor. The method is described by Foster and Wong, *Br J Pharmacol* 91, 403-409 (1987).
- 5 c) **NMDA and glycine receptor affinity** may also be tested in the [³H]L-glutamate and [³H]glycine binding assays following the method of Monaghan & Cotman, *PNAS*, 83, 7532, (1986) and Watson *et al*, *Neurosci Res Comm*, 2, 169, (1988).
- d) **Antihypoxia activity** may be measured conveniently in mice. Groups of mice are tested at various times after the intraperitoneal administration of graded doses of
10 the test compound. The animals' survival time in a temperature-controlled hypoxic environment (96% nitrogen and 4% oxygen) is recorded. A statistical comparison is made between coincident vehicle treated animals and the experimental group. The dose-response and minimum active dose (MAD) for compounds are obtained [A A Artu and J D Michenfelder, *Anaesthesia and Analgesia*, 1981, 60, 867]. Other modes of
15 administration can also be used.
- e) **Antiepileptic activity** may be measured by assessing a compound's ability to prevent the hind limb tonic extension component of the seizure in groups of mice or rats induced by maximal electroshock (MES) after oral, intraperitoneal, intravenous or subcutaneous administration, according to the procedures of the Epilepsy Branch,
20 NINCDS as published by R J Porter, *et al*, *Cleve Clin Quarterly* 1984, 51, 293, and compared with the standard agents dilantin and phenobarbital.
- f) **The 4-vessel occlusion (4-VO) model of stroke** is used to produce global ischaemia in the rat and is an essential technique to evaluate the effectiveness of compounds to prevent damage to areas of selective vulnerability in the brain, notably the
25 CA1 pyramidal neurons of the hippocampus. This area is involved in the pathways for short term memory formation in both laboratory animals and humans. The procedure consists of cauterizing the vertebral arteries and isolating the carotid arteries of rats maintained under anaesthesia on day 1. On day 2 the carotids are clamped for varying periods of time, ten minutes is sufficient to destroy the CA1 neurons. The clamps are
30 removed, reflow initiated and drugs administered at various times post reflow. Body temperature is maintained at 37°C throughout the ischaemia and recovery periods. The CA1 neurons die off over a 48-72 hour period and normally the rats are treated for at

least 3 days with drug (ip, iv, or po) and at 7 days the brains are removed for histology. Rating of CA1 damage is accomplished using two methods, counting of viable CA1 neurons and scoring of degree of gross pathology [W A Pulsinelli and A Buchan, 'The NMDA receptor/ion channel: Its importance to in vivo ischemia injury to selectively
5 vulnerable neurons', Pharmacology of Cerebral Ischemia, edited by J Krieglstein and H Oberpichler, published by Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1990, p169].

g) In the **Focal Model of Stroke**, spontaneously hypertensive rats (SHR) are used as experimental subjects because of their relatively poor collateral brain circulation. A 2 hour focal ischemia is achieved in SHR by clamping the middle cerebral artery and
10 the ipsilateral carotid while maintaining anaesthesia. Drugs can be administered (usually ip) either before or at various times after clamping the arteries or when reflow commences at 2 hours. The brains are removed 24 hours after the experiment and frozen, sectioned and drug effects toward reducing infarct volume of the cerebral cortex is determined using a custom-built computer quantification system [A M Buchan, D Xue
15 and A Slivka, Stroke, 1992, 23, 273.]

The toxicity of the compound of the invention may be measured in the following tests.

a) **Dose ranging studies** based on those described by N W Spurling and P F Carey,
20 'A protocol for dose selection in repeat dose toxicity studies', poster presentation 974 at the Society of Toxicology annual meeting, Seattle, USA, 23-27 February 1992. Rats are dosed intravenously daily with progressively increasing doses of test compound until a maximum repeatable dose is found above which the incidence of convulsions and other abnormal clinical signs is unacceptable.

25 b) **The inverted screen test** [L L Cougenour, J R McLean, and R B Parker, Pharmacol Biochem Behav, 1977, 6, 351]. Mice are dosed with test compound and 30 minutes later are placed on a small wire platform which is inverted through an arc of 180°. Mice unable to climb to the upright position within 30 seconds are rated as failures. Using sufficient doses and numbers of animals an appropriate TD₅₀ (dose in which 50% fail)
30 can be determined readily.

c) **The observation test for 28 behavioral signs** according to S Irwin [Psychopharmacology 1968, 13, 222]. Groups of 3 mice per dose are administered incremental

amounts of test compound in the range 25-400 mg/kg and observed for 28 symptoms immediately after dosing, 30 minutes, 3 hours and 24 hours post dose.

d) **Test for Phencyclidine (PCP)-Like Behaviour.** PCP-like behaviours are a side effect of potent competitive and non-competitive NMDA receptor antagonists. In a screen to determine whether a compound possesses this liability, rats are dosed orally with test compound (expressed as multiples of the oral ED₅₀ for protection in the MES test) and placed into individual clear plastic cages and observed over a 4 hour period for any incidence of 5 characteristic behaviours associated with PCP, namely hyperactivity, ataxia, circling, head weaving and retropulsion. Five rats per treatment group are observed and compared to a control group receiving PCP. A total incidence score would be 25, *i.e.* 5 rats exhibiting all 5 behaviours. PCP at 10 times the ED₅₀ produces a score of 25 [W Koek, J H Woods, P Ornstein, 1987, *Psychopharmacology*, 91, 297].

e) **Gang Plank Escape Test** to measure neural impairment in rats [G E Garske *et al*, *Epilepsy Research*, 1991, 9, 161]. Rats are placed on a narrow board (1.25cm wide suspended 40cm above the bench top) in a well lit entry cubicle which enters a progressively darkened box connected to a dark escape cubicle at the other end (board is 63cm long). A rat is impaired if it fails to negotiate the plank. The task takes into account two known behaviours of rats, *i.e.* fear of height and seeking a dark environment.

Linear pharmacokinetics may be detected in rats by evaluating the area under the plasma concentration v time curves obtained upon single intravenous administration of test compound at increasing doses (Smith *et al*, *Xenobiotica*, 20, 1187-1199, 1990). Blood was removed from a jugular vein catheter at various times over a 24 hour period. The plasma was separated by centrifugation and the concentration of test compound was determined using HPLC-UV chromatography. The plasma concentration v time values were plotted for each dose and the area under each curve estimated. Where linear pharmacokinetics are present, the area under the plasma concentration v time curve for a given dose is directly proportional to the dose administered. A finding of linear pharmacokinetics in rats indicates that linear pharmacokinetics would be found in humans (Leander *et al*, *Epilepsia*, 33, 696-704, 1992, at p703).

According to another aspect of the invention there is provided a method of treatment of a neurodegenerative disorder, which comprises administering a therapeutically effective amount of the compound of the invention to a patient. Of particular interest is such a method in which the dose of the compound administered is linearly proportional
5 to the blood plasma concentration of the compound desired.

For the above-mentioned uses the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compound of the invention are
10 administered at a daily dosage of from about 0.1mg to about 20mg per kg of animal body weight, preferably given in divided doses 1 to 4 times a day or in sustained release form. For man, the total daily dose is in the range of from 5mg to 1,400mg, more preferably from 10mg to 100mg, and unit dosage forms suitable for oral administration comprise from 2mg to 1,400mg of the compound admixed with a solid or liquid pharma-
15 ceutical carrier or diluent.

The compound of the invention may be used on its own or in the form of appropriate medicinal preparations for enteral or parenteral administration. According to a further aspect of the invention, there is provided a pharmaceutical formulation including prefer-
20 ably less than 80% and more preferably less than 50% by weight of the compound of the invention in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

Examples of diluents and carriers are:

- 25 for tablets and dragees: lactose, starch, talc, stearic acid;
- for capsules: tartaric acid or lactose;
- for injectable solutions: water, alcohols, glycerin, vegetable oils;
- for suppositories: natural or hardened oils or waxes.

30 An adjuvant of particular interest when the compound of the invention is to be used in the treatment of Parkinson's disease is L-dopa.

According to a further aspect of the invention, there is provided the use of the compound of the invention as active ingredient in the manufacture of a medicament for the treatment of a neurodegenerative disorder.

- 5 The compound of the invention may also have the advantage that it is less toxic, more efficacious, is longer acting, has a broader range of activity, is more potent, produces fewer side effects, is more easily absorbed or has other more useful pharmacological properties, than compounds previously indicated in the therapeutic fields mentioned above.

10

The invention is illustrated by the following examples.

Example 1

Preparation of (S)- α -phenyl-2-pyridineethanamine dihydrochloride

15

a) α -Phenyl-2-pyridineethanamine dihydrochloride

To a cooled (0°C) solution of benzaldehyde (34.24g, 0.323 moles) in 600ml of tetrahydrofuran (THF) was added lithium bis(trimethylsilyl)-amide (LHMDS) (323ml of a 1.0M solution in THF, 0.323 moles) dropwise over 30 minutes. This mixture was stirred
20 at 0°C for three hours.

In a separate round bottom flask containing a cooled (-78°C) solution of 2-picoline (30.0g, 0.323 moles) in THF (600ml) was added n-butyllithium (n-BuLi) (129.2ml of a 2.5M solution in hexane) over twenty minutes.

25

The first reaction mixture was allowed to warm to 0°C and remain there for an additional forty minutes. The second reaction mixture (containing the lithiated anion of 2-picoline) was cannulated into the first reaction mixture over 20 minutes. After 30 additional minutes the cold bath was removed and the mixture was allowed to warm to
30 ambient temperature. After an additional one hour, the reaction mixture was poured into a separating funnel charged with ice (1l) and 12 N HCl (200ml). The aqueous layer was washed with 3x200ml of diethyl ether (Et₂O) and then basified with 25% NaOH solution in water. The aqueous layer was extracted with 2x200ml of chloroform, the

chloroform extracts dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was dissolved in ethyl acetate (EtOAc) and acidified with a saturated solution of HCl/EtOAc. The solution was diluted with Et_2O and the resulting white solid filtered and dried *in vacuo* to give the subtitle compound (37.08g, 43%), mp = 206-208°C.

5

b) (S)- α -Phenyl-2-pyridineethanamine dihydrochloride

To a solution of racemic α -phenyl-2-pyridineethanamine (the free base of the product of step (a), obtained by neutralizing an aqueous solution of the product of step (a) with a 25% NaOH solution in water and extracting with chloroform) (10.96g, 0.0553 moles) in EtOAc (400ml) was added a solution of S(+)-mandelic acid (8.41g, 0.0553 moles) in EtOAc (300ml). The resulting precipitate was recrystallized from hot EtOAc (500ml) an additional three times. The salt was basified with a 25% NaOH solution in water, extracted with 3x100ml of chloroform, dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was dissolved in EtOAc (300ml) and acidified with a saturated solution of HCl/EtOAc. The resulting white solid was filtered and dried *in vacuo* to give (-)- α -phenyl-2-pyridineethanamine dihydrochloride (5.5g), mp = 220-222°C, $[\alpha]_D = -87.3^\circ$ (c = 1.0, CH_3OH).

The filtrate from the initial precipitation was neutralized with 25% NaOH solution in water, extracted with 2x250ml of CHCl_3 , dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was dissolved in EtOAc (500ml) and to this solution was added a solution of R(-)-mandelic acid (6.5g, 0.043 moles) in EtOAc (500ml). The precipitate was filtered off and recrystallized an additional three times. The salt was basified with 25% NaOH solution in water, extracted with 3x100ml of chloroform, dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was dissolved in EtOAc (300ml) and acidified with a saturated solution of HCl/EtOAc. The resulting white solid was filtered and dried *in vacuo* to give the title compound (3.84g), mp = 220-222°C, $[\alpha]_D = +87.1^\circ$ (c = 1.1, CH_3OH).

30 The enantiopurity may be determined by derivatizing either the mandelic acid or dihydrochloride salt with enantiopure (greater than 99.5%) methylbenzyl isocyanate, and then analyzing by HPLC using a normal phase column with ethanol/hexane [6:94] as solvent.

The enantiopurity of the enantiomers obtained above was shown to be greater than 99.5%.

X-ray crystallography showed the (+)-enantiomer to have (*S*)-absolute stereochemistry.

5

Example 2

Preparation of (*S*)- α -phenyl-2-pyridineethanamine (*S*)-malate from (*S*)- α -phenyl-2-pyridineethanamine dihydrochloride

- 10 To a solution of 3.0g of the title compound of Example 1 in 100ml of ethyl acetate was added a saturated solution of (*S*)-malic acid (99%, Aldrich Chemical Company Limited, >99.8% enantiopure) in ethyl acetate until the resulting mixture became acidic. The resulting precipitate was dissolved by the addition of methanol and precipitated by the addition of ether. The resulting white solid was filtered off, and dried *in vacuo* to yield
- 15 3.85g of the title compound. mp = 134-136°C; $[\alpha]_D = +51.02^\circ$ (c=0.9957, CH₃OH, 23°C); enantiopurity of the amine moiety >99.999%.

Example 3

Preparation of (*S*)- α -phenyl-2-pyridineethanamine (*S*)-malate from α -phenyl-2-pyridine-

20 ethanamine dihydrochloride

- A solution containing 5.95g (30.1mmole) of the compound of Example 1(a) and 4.8g (35.8mmole) of (*S*)-malic acid (99%, Aldrich Chemical Company Limited, >99.8% enantiopure) in a total of 250ml of acetone was heated until all solids had dissolved, a
- 25 small amount of methanol was required to effect complete dissolution. The solids that formed upon cooling were collected and recrystallized twice from 250ml of hot acetone, again a small amount of methanol was required to effect complete dissolution. The resulting product was collected and dried *in vacuo* to yield 2g of the title compound. $[\alpha]_D = +50.03^\circ$ (c=0.9563, CH₃OH, 23°C); enantiopurity of the amine moiety = 99.8%.

30

Example 4

The stability of the title compound of Example 1 and the title compound of Example 2 to moisture was investigated. The former compound was found to deliquesce at a relative humidity of 80%, whereas the latter compound absorbed only 0.1% of its own weight of water at the same relative humidity.

5

Example 5

The title compound of Example 2 was found to have an activity (ED_{50}) of 2.9mg/kg in the prevention of hind limb tonic extension in rats induced by maximal electroshock
10 (MES) (described above) when administered orally.

The claims defining the invention are as follows:

1. A selected (S)- α -phenyl-2-pyridineethanamine salt having useful pharmacokinetic properties such that when used in the treatment of neurodegenerative disorders in a patient, the blood plasma concentration obtained is linearly proportional to the dose administered, said selected salt being the (S)- α -phenyl-2-pyridineethanamine (S)-malate, in having non-hygroscopic property effective to provide such stability as to be ideally suitable for pharmaceutical formulation.

2. (S)- α -phenyl-2-pyridineethanamine (S)-malate according to claim 1 which is greater than 90% enantiopure.

3. (S)- α -phenyl-2-pyridineethanamine (S)-malate according to claim 1 which is greater than 99% enantiopure.

4. A pharmaceutical formulation including (S)- α -phenyl-2-pyridineethanamine (S)-malate as defined in any one of claims 1 to 3, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

5. The use of (S)- α -phenyl-2-pyridineethanamine (S)-malate as defined in any one of claims 1 to 3, as active ingredient, in the manufacture of a pharmaceutical formulation, said pharmaceutical formulation being suitable for the treatment of a neurodegenerative disorder in a patient.

6. A method of treatment of a neurodegenerative disorder in a patient in need of such treatment, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical formulation containing (S)- α -phenyl-2-pyridineethanamine (S)-malate as defined in claim



7. A method of treatment as claimed in claim 6, wherein the dose of the compound administered is linearly proportional to the blood plasma concentration of the compound desired.


5 8. A process for the production of (S)- α -phenyl-2-pyridineethanamine (S)-malate as defined in any one of claims 1 to 3, which comprises: (a) precipitation from a solution of a mixture of (S)- α -phenyl-2-pyridineethanamine, or a salt thereof, and (S)-malic acid which is greater than 90%
10 enantiopure; or (b) precipitation from a solution of a mixture of (S)- α -phenyl-2-pyridineethanamine or a salt thereof, which is greater than 90% enantiopure, and (S)-malic acid which is greater than 90% enantiopure.

15 9. A process as claimed in claim 8, wherein the (S)- α -phenyl-2-pyridineethanamine, or a salt thereof, in said solution, is greater than 99% enantiopure.

10. (S)- α -phenyl-2-pyridineethanamine (S)-malate according to any one of claims 1 to 3 when obtained by the process of claim 8 or 9, respectively.

DATED this 18th day of July 1997

ASTRA AKTIEBOLAG,
By its Patent Attorneys,
E. F. WELLINGTON & CO.,
By:


(Bruce S. Wellington)

A/KA/4218



INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 94/00651

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D213/38 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 356 035 (FISONS CORPORATION) 28 February 1990 cited in the application see page 6, line 57 ---	1-9
Y	J.B. TAYLOR 'Comprehensive medicinal chemistry Vol.5 Biopharmaceutics', PERGAMON PRESS, OXFORD * page 379 lines 9-13 * ---	1-9
Y	EP,A,0 472 325 (KISSEI PHARMACEUTICAL CO.) 26 February 1992 see page 2, line 40 - page 3, line 18 ---	1-9
Y	US,A,3 422 191 (A. HALPERN ET AL.) 14 January 1969 --- -/--	1-9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 June 1994

Date of mailing of the international search report

21.06.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

Int'l Application No.

PCT/GB 94/00651

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO, A, 93 20052 (FISONS CORPORATION) 14 October 1993 cited in the application -----	1-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB94/00651

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 7 and 8 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 94/00651

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0356035	28-02-90	DK-A- 8903941	13-02-90
		WO-A- 9111995	22-08-91
		JP-A- 2131452	21-05-90
EP-A-0472325	26-02-92	JP-A- 4095072	27-03-92
		AU-B- 646276	17-02-94
		AU-A- 8145891	13-02-92
		CA-A- 2048714	09-02-92
US-A-3422191	14-01-69	NONE	
WO-A-9320052	14-10-93	AU-B- 3897693	08-11-93